| |
| |
|
| Insider
Information: |
Ocampo Christine |
| Relationship: |
PAO; CAO/Urovant Scien... |
| City: |
Foothill Ranch |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
130,387 |
|
|
Indirect Shares
|
3,000 |
|
|
| Direct
Value |
$44,475 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
133,387 |
|
|
| Total
Value |
$44,475 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Avanir Pharmaceuticals |
AVNR |
Vice President, Finance |
2014-12-18 |
108,797 |
2014-05-16 |
3,000 |
Premium* |
|
|
Eledon Pharmaceuticals Ord Shs |
ELDN |
See Remarks |
2017-05-10 |
21,590 |
2017-05-10 |
0 |
Premium* |
|
|
Urovant Sciences Ltd. |
UROV |
PAO; CAO/Urovant Scien... |
2021-03-29 |
0 |
2020-01-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| UROV |
Urovant Sciences Ltd. |
PAO; CAO/Urovant Sciences,Inc. |
• – – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(78,781) |
0 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PAO;CAO/Urovant Sciences, Inc |
• – – |
2020-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
44,346 |
77,179 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PAO;CAO/Urovant Sciences, Inc |
• – – |
2020-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
32,833 |
32,833 |
0 |
- |
|
| ELDN |
Eledon Pharmaceuticals Or... |
See RemarksOfficer |
• – – |
2017-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,580 |
|
- |
|
| ELDN |
Eledon Pharmaceuticals Or... |
See Remarks |
• – – |
2017-05-10 |
4 |
B |
$9.99 |
$100,000 |
D/D |
10,010 |
21,590 |
2.74 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2014-12-18 |
4 |
AS |
$16.93 |
$97,855 |
D/D |
(5,780) |
108,797 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2014-12-16 |
4 |
AS |
$16.94 |
$508,200 |
D/D |
(30,000) |
114,577 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2014-12-16 |
4 |
OE |
$2.59 |
$105,525 |
D/D |
30,000 |
144,577 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2014-11-10 |
4 |
A |
$0.00 |
$0 |
D/D |
51,836 |
114,577 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2014-10-24 |
4 |
AS |
$11.81 |
$24,565 |
D/D |
(2,080) |
77,791 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2014-09-15 |
4 |
AS |
$9.45 |
$519,750 |
D/D |
(55,000) |
79,871 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2014-08-26 |
4 |
AS |
$6.10 |
$12,871 |
D/D |
(2,110) |
79,871 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2014-05-16 |
4 |
S |
$4.88 |
$58,072 |
I/I |
(11,900) |
3,000 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2014-05-14 |
4 |
S |
$5.13 |
$131,307 |
D/D |
(25,596) |
81,981 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2014-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
44,375 |
107,577 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2013-12-18 |
4 |
AS |
$2.63 |
$6,445 |
D/D |
(2,450) |
63,202 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2013-05-15 |
4 |
AS |
$3.28 |
$255,250 |
D/D |
(77,700) |
65,652 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2013-05-15 |
4 |
OE |
$0.88 |
$50,776 |
D/D |
57,700 |
123,352 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2012-12-17 |
4 |
A |
$0.00 |
$0 |
D/D |
30,251 |
85,652 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2012-12-03 |
4 |
AS |
$2.55 |
$7,258 |
D/D |
(2,845) |
55,401 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2012-09-17 |
4 |
AS |
$3.49 |
$226,824 |
D/D |
(65,000) |
58,246 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2012-09-17 |
4 |
OE |
$0.53 |
$34,450 |
D/D |
65,000 |
123,246 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2012-03-06 |
4 |
B |
$2.60 |
$7,795 |
I/I |
3,000 |
3,000 |
1.99 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2011-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
58,246 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Vice President, Finance |
• – – |
2011-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,350 |
40,922 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
